Core Viewpoint - The article discusses the outbreak of Chikungunya fever in China and globally, highlighting the urgent need for effective detection and prevention measures due to the lack of specific treatments and vaccines [2][3]. Group 1: Current Situation - As of July 23, 2025, Foshan reported a total of 3,645 confirmed cases of Chikungunya fever, with the Shunde District accounting for 3,317 cases, an increase of 383 cases from the previous day [2]. - The World Health Organization (WHO) has warned that 119 countries and regions are experiencing virus transmission, with approximately 5.5 million people at risk of infection, potentially straining healthcare systems [2]. Group 2: Prevention and Control - There are currently no specific drugs or vaccines for Chikungunya fever; the primary prevention strategy is mosquito control, including eliminating breeding sites and using personal protective measures [3]. - The clinical features of Chikungunya fever include acute fever, severe joint pain, and rash, with higher risks for children, the elderly, and immunocompromised individuals [3]. Group 3: Diagnostic Methods - Common diagnostic methods for Chikungunya fever include serological testing, nucleic acid testing, and virus isolation, with specific timelines for sample collection to ensure accurate results [4]. - Currently, there are no approved test kits for Chikungunya fever in China, which poses a challenge for timely diagnosis [4]. Group 4: Market Opportunities - Several domestic companies, including DaAn Gene, Wanfu Biology, and Shengxiang Biology, are developing Chikungunya fever detection solutions based on PCR methodologies, with others exploring high-throughput sequencing and antigen-antibody detection methods [5]. - The ongoing outbreak is expected to accelerate the accumulation of clinical data for these detection products, potentially speeding up their approval and market entry [5].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology sector [4]. Core Insights - The number of confirmed cases of Chikungunya fever is rapidly increasing, with 3,645 cases reported in Foshan as of July 23, 2025, including a daily increase of 383 cases in Shunde District [1]. - The World Health Organization (WHO) has warned that 119 countries and regions are at risk of virus transmission, with approximately 5.5 million people facing infection risk [1]. - There are currently no specific drugs or vaccines available for Chikungunya fever, making mosquito control the primary prevention strategy [2]. - Multiple companies have launched testing solutions for Chikungunya fever, and the approval of these products is expected to accelerate [3]. Summary by Sections Industry Overview - Chikungunya fever is caused by the Chikungunya virus (CHIKV) and primarily transmitted by Aedes mosquitoes, with symptoms including acute fever and severe joint pain [2]. - The absence of effective treatment and vaccines necessitates supportive care and preventive measures such as mosquito control [2]. Testing Solutions - Common testing methods for Chikungunya fever include serological testing, nucleic acid testing, and virus isolation, but no test kits have been approved for sale in China [2]. - Companies like DaAn Gene, Wanfu Biology, and others have developed PCR-based testing solutions, while others are exploring high-throughput sequencing methods [3]. Investment Opportunities - The report suggests focusing on companies that have developed Chikungunya testing solutions, including DaAn Gene, Wanfu Biology, and others [3].

Core Viewpoint - The epidemic of Chikungunya fever in Guangdong Province remains at a high plateau, indicating a severe situation that requires attention [1]. Summary by Sections Epidemic Situation - As of July 22, 2025, Shunde District in Foshan City reported a total of 2,934 confirmed cases of Chikungunya fever, with a significant increase of 463 cases in just one day [4][5]. - The first report of the epidemic in Shunde was on July 15, 2025, with 478 confirmed cases, showing an increase of over 2,000 cases in just over a week [4]. - The World Health Organization (WHO) reported that 119 countries and regions have identified Chikungunya virus transmission, with approximately 5.5 million people at risk globally, potentially leading to widespread outbreaks [4][5]. Companies Involved in Prevention and Detection - **Runben Co., Ltd. (润本股份)**: A leading domestic company in mosquito repellent products, with a revenue of 440 million yuan in 2024, showing a year-on-year growth of 35.4% and a gross margin of 54.2% [7]. - **Rainbow Group (彩虹集团)**: A well-known pest control company in China, offering a full range of mosquito repellent products that play a crucial role in controlling Chikungunya fever [8]. - **Shanghai Jahwa (上海家化)**: The "Liushen" brand is the top brand in China for mosquito repellent flower water, holding significant brand influence in mosquito prevention and personal care [9]. - **Longyun Group (朗云集团)**: A Hong Kong-listed company that has maintained the number one market share in pest control products for ten consecutive years, with notable products performing well during the epidemic [10]. - **Kangzhi Pharmaceutical (康芝药业)**: Offers a full range of baby and child health protection products, including disinfectants and mosquito repellents, demonstrating expertise in child health protection [11]. - **Shuoshi Gene (硕世纪录物)**: Utilizes gene sequencing technology for Chikungunya fever testing, providing precise diagnostic support for epidemic prevention [12]. - **Da'an Gene (达安基因)**: Provides nucleic acid testing kits for Chikungunya virus, leveraging extensive experience in molecular diagnostics [13]. - **Huiyu Medical (会域医学)**: A leading medical testing institution in China, employing advanced technology for accurate diagnosis of Chikungunya fever [14]. - **Wansheng Biology (万学生物)**: Offers rapid testing solutions for Chikungunya virus, focusing on point-of-care testing [16]. - **Nuo Weisha (诺唯莎)**: Combines molecular design with various heat-start technologies to enhance detection efficiency for mosquito-borne viruses [17].

硕世生物：公司有基孔肯雅病毒检测试剂盒 仅供科研使用 智通财经7月24日电，硕世生物在互动平台表示，公司蚊传虫媒病毒系列产品线中有基孔肯雅病毒检测 试剂盒。该产品目前仅供科研使用，未对公司当前收入及利润产生重大影响。 ...

特此公告。 江苏硕世生物科技股份有限公司董事会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 江苏硕世生物科技股份有限公司（以下简称"公司"）于 2025 年 7 月 16 日披露了《江苏硕世生物科技股份有限公司关于控股股东股权结构变动的提示性 公告》(公告编号：2025-018)，公司控股股东绍兴闰康生物医药股权投资合伙企 业（有限合伙）（以下简称"闰康生物"）的股权结构发生变化，南京高科新创 投资有限公司将其持有的闰康生物 7.0449%的股权转让给泰州硕越股权投资合 伙企业（有限合伙）。 公司于近日收到闰康生物的通知，确认上述股权转让的工商变更登记手续已 经办理完成。截至本公告披露日，上述股权转让款项已支付完毕。本次控股股东 的股权结构变化后，公司的控股股东和实际控制人均未发生变化，控股股东及一 致行动人合计持股数量未发生变化。 敬请广大投资者理性投资，注意投资风险。 证券代码：688399 证券简称：硕世生物 公告编号：2025-019 江苏硕世生物科技股份有限公司 关于公司控股股东股权结构变动的进展公告 202 ...

江苏硕世生物科技股份有限公司 关于公司控股股东股权结构变动的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●本次变动属于江苏硕世生物科技股份有限公司（以下简称"公司"）控股 股东绍兴闰康生物医药股权投资合伙企业（有限合伙）（以下简称"闰康生物"） 股权结构变动，未导致其所持有的公司股份数量及持股比例发生变化，不会对公 司经营产生重大影响，不触及要约收购。 ●本次变动未涉及公司控股股东及实际控制人变更，控股股东及一致行动人 合计持股数量未发生变化。 公司于近日收到公司控股股东闰康生物关于股权结构变更的通知，现将具体 情况公告如下： 一、本次变动前后控股股东股权结构的情况 证券代码：688399 证券简称：硕世生物 公告编号：2025-018 控股股东股权结构变更后，公司与控股股东、实际控制人及其一致行动人的 股权结构关系如下图所示： 二、泰州硕越基本情况 企业名称 泰州硕越股权投资合伙企业（有限合伙） 近期，泰州硕越股权投资合伙企业（有限合伙）（以下简称"泰州硕越"） 与南京高科新创投资有限公司 ...

证券代码：688399 证券简称：硕世生物 公告编号：2025-018 江苏硕世生物科技股份有限公司 关于公司控股股东股权结构变动的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ●本次变动属于江苏硕世生物科技股份有限公司（以下简称"公司"）控股 股东绍兴闰康生物医药股权投资合伙企业（有限合伙）（以下简称"闰康生物"） 股权结构变动，未导致其所持有的公司股份数量及持股比例发生变化，不会对公 司经营产生重大影响，不触及要约收购。 ●本次变动未涉及公司控股股东及实际控制人变更，控股股东及一致行动人 合计持股数量未发生变化。 | 梁锡林 | 4,500.0000 | 71.8846% | 4,500.0000 | 71.8846% | | --- | --- | --- | --- | --- | | 房永生 | 500.0000 | 7.9872% | 500.0000 | 7.9872% | | 高科新创 | 441.0112 | 7.0449% | | | | 泰州硕越 | 819.0209 | ...

Group 1 - Hengbang Co., Ltd. plans to establish a joint venture with Huasheng Development with a registered capital of 10 million yuan, where Hengbang will contribute 8 million yuan (80%) and Huasheng will contribute 2 million yuan (20%) [1] - Hunan Gold's subsidiary Anhua Zhazi Creek Smelting Plant will undergo temporary maintenance starting from the end of June 2025, expected to last no more than 30 days [2] - Defu Technology's subsidiary signed supply agreements for lithium battery copper foil products with two leading global companies, with contract durations of 3 years and 5 years respectively [3] Group 2 - Binjiang Group won the rights to two residential land parcels for a total price of 4.368 billion yuan [5] - Zhong'an Technology announced the resignation of its executive vice president and board secretary due to personal reasons [7] - Changqing Technology's project for special polymer materials and electronic materials has officially commenced production, adding a capacity of 120,500 tons per year [10] Group 3 - Gansu Energy received approval from the China Securities Regulatory Commission to publicly issue bonds totaling up to 2 billion yuan [10] - Shuoshi Biology obtained a medical device registration certificate for an in vitro diagnostic reagent, valid until June 2030 [12] - Yawen Co., Ltd. plans to issue shares to specific investors, with the application accepted by the Shenzhen Stock Exchange [13] Group 4 - Guoyao Modern's subsidiary received approval for the listing of a raw material drug, which is a selective anticholinergic agent [16] - Inner Mongolia First Machinery's subsidiary signed a railway freight car procurement contract worth 130 million yuan [18] - Xining Special Steel plans to raise up to 1 billion yuan through a private placement to its controlling shareholder [39] Group 5 - Huadong Medicine's subsidiary received approval for a clinical trial of a new injectable drug targeting advanced solid tumors [29] - Warner Pharmaceutical's compound potassium hydrogen phosphate injection passed the consistency evaluation for generic drugs [30] - North Special Technology plans to raise up to 300 million yuan through a private placement for a production base project in Thailand [30] Group 6 - Xiangyang Technology is the first candidate for a 533 million yuan Airbus project [45] - Haishun New Materials intends to acquire 100% of Guangdong Zhengyi Packaging [46] - Jida Zhengyuan's shareholder plans to reduce their stake by up to 0.73% due to personal financial needs [47]

证券代码：688399 证券简称：硕世生物 公告编号：2025-017 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上述产品获证后的实际销售情况取决于未来市场的推广效果以及市场的实 际需求，公司目前尚无法预测其对公司未来业绩的影响。敬请广大投资者谨慎投 资、注意投资风险。 江苏硕世生物科技股份有限公司（以下简称"公司"）近日收到国家药品监 督管理局签发的医疗器械注册证（体外诊断试剂），具体信息如下： 特此公告。 一、医疗器械注册证的具体情况 | 序号 | 产品名称 | 注册编号 | 注册证 | 注册 | 预期用途 | | --- | --- | --- | --- | --- | --- | | | | | 有效期 | 分类 | | | 1 | 肺炎支原体核酸检测 | 国械注准 | 至 2030 年6月26 | 三类 | 本试剂用于体外定性检 测咽拭子、痰液样本中的 | | | 试剂盒(荧光 PCR 法) | 20253401261 | 日 | | 肺炎支原体核酸。 | 二、对公司的影响 上述《医疗器械注册证》的取得， ...

Core Viewpoint - The company has received a medical device registration certificate from the National Medical Products Administration for its Mycoplasma pneumoniae nucleic acid detection kit (fluorescent PCR method), enhancing its product range and competitiveness in the in vitro diagnostics field [1] Group 1 - The product is classified as a Class III medical device with registration number 20253401261 and is valid until June 26, 2030 [1] - The kit is designed for the qualitative detection of Mycoplasma pneumoniae nucleic acid in throat swabs and sputum samples [1] - The acquisition of this registration certificate is expected to improve the company's market expansion capabilities [1] Group 2 - The actual sales performance of the product will depend on market promotion effectiveness and demand [1] - The company is currently unable to predict the impact of this product on its financial performance [1]